Bruce Power announces milestone in medical Lu-177 production

June 24, 2022, 12:01PMNuclear News
The new IPS installed in Bruce Power’s Unit 7 will produce Lu-177 for treating cancer. (Photo: Bruce Power)

An international collaboration between Bruce Power, Isogen (a joint venture of Kinectrics and Framatome), and ITM Isotope Technologies Munich SE, announced a milestone marking the first time that lutetium-177, a short-lived medical radioisotope, has been produced in a commercial nuclear power reactor.

To continue reading, log in or create a free account!

Related Articles

Constellation appoints new nuclear chief

September 5, 2025, 7:01AMNuclear News

Longtime nuclear industry executive Chris Mudrick has been named the new chief nuclear officer at Constellation Energy, effective September 29. He will take over the position from Dave...

Nuclear's future discussed at MURR expansion

April 7, 2025, 3:05PMANS News

ANS Executive Director/CEO Craig Piercy recently spoke on nuclear power’s potential for answering today’s energy demands as part of the Distinguished Lecture Series at the University of...